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Abstract Human plasma has been shown to contain a low mo- 
lecular weight factor that potentiates human IGF-I stimulation 
of glycosaminoglycan synthesis in chick embryo cartilage. The 
peptide was purified and characterized by Edman degradation 
and electrospray mass spectrometry. The primary structure de- 
termined was: Trp-Gly-His-Glu. A homologous synthetic peptide 
similarly promoted matrix biosynthesis in cartilage exposed to 
1GF-I. 
k2ey words: Glycosaminoglycan synthesis; Insulin-like growth 
lactor I; Peptide purification; Wound repair; Human plasma; 
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Daltons (Da), that were necessary for the sulfation activity of 
IGF-I  in chick embryo pelvic leaflets. In view of their size and 
biological properties, they were named low molecular weight 
growth promoting factors (LMW-GFs). The bioassay [14] was 
used in the purification of several molecular forms of the IGFs 
from human COHN paste IV [15] or fetal ovine serum [16]. 
We now describe the complete isolation and characterization 
of a tetrapeptide from normal human plasma, which modulates 
the effects of recombinant human (rh) IGF-I  on proteoglycan 
synthesis in cultured chick embryo cartilage. Its identity was 
confirmed using a synthetic peptide with identical electro- 
phoretic migration and biological activity. 
2. Materials and methods 
I. Introduction 
Insulin-like growth factors ( IGF-I  and IGF-I I)  are single- 
hain polypeptides that have structural homology with proin- 
~ulin [1-3]. They have been shown to regulate proliferation and 
,!ifferentiation i numerous cell types (review in [4]). Unlike 
~asulin, they are produced in most tissues and are abundant in 
he bloodstream, thus acting via endocrine, as well as autocrine 
~nd/or paracrine, mechanisms [5]. 
One of the initially recognized biological activities of the 
GFs  was their ability to stimulate sulfated mucopolysac- 
haride synthesis in articular cartilage [6]. They were found not 
, ,nly to promote sulfation of the glycosyl residues in proteogly- 
ans, the final step in glycosaminoglycan biosynthesis, but also 
o enhance synthesis of the core protein [7] and elongation of 
,,xisting chontroitin sulfate chains [8,9]. 
Early purification protocols for IGF- I  and IGF- I I  were mon- 
tored by measuring the stimulation of [35S]sulfate uptake into 
a t  [10], chick embryo [11] and pig [12] cartilage xplants. How- 
:ver, Froesch et al. [6] demonstrated that highly purified IGFs 
)er se failed to stimulate [35S]sulfate incorporation into chick 
,'mbryo cartilage, but that, when added to serum from hypothy- 
old, hypophysectomized rats, which itself exerted no stimula- 
ion, they became potent sulfation factors. 
Heulin et al. [13] in our laboratory found that human serum 
:ontained factors with molecular weights (MWs) below 1000 
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4bbreviations: IGF, insulin-like growth factor; Da, Daltons; rh, recom- 
:ginant human; MW, molecular weight; RP HPLC, reverse phase high- 
;~erformance liquid chromatography; Boc, t-Butyloxycarbonyl; BOP, 
Castro's reagent; TFA, trifluoroacetic a id. 
2.1. Isolation 
2.1.1. Part&l purification; Gel permeation chromatography. LMW- 
GF was partially purified from normal human plasma as previously 
described [16]. Briefly, 15 liters human plasma were ultrafiltered 
through aPTAC membrane (1000-Da cut-off; Millipore, Bedford, MA, 
USA) at 4°C. Ultrafiltration was stopped when retentate volume 
reached 1/3 of the original volume. The ultrafiltrate (10 liters) was 
extracted (v/v) with chloroform for 24 h at 4°C so as to remove hydro- 
phobic molecules uch as steroid hormones. The lyophilized aqueous 
phase (50 ¢tg peptide/ml ultrafiltrate, as determined according to 
Sargent [18]) was applied to a 100 × 10-cm column packed with 200- 
400-mesh Biogel P2 (BioRad, Hercules, CA, USA). Elution was carried 
out using distilled water at a flow rate of 150 ml/h. Fractions were 
collected over a period of 20 min and their biological activities meas- 
ured as described below. 
2.1.2. Reverse phase HPLC purification of the tetrapeptide. Biogel 
P2-active fractions eluted between Kay 0.45 0.65 (370 700 Da) from 
four successive runs were pooled for further purification. 
Lyophilized samples were dissolved in 100 ml 0.1% (v/v) trifluoroace- 
tic acid (TFA)/water and pumped (20 ml) at a flow rate of 2 ml/min onto 
a 250 x 10-mm Vydac C~s reverse-phase (RP) HPLC column (Separa- 
tions Group, Hesperia, CA, USA) equilibrated with the same buffer 
(0.1% TFA in water: Solvent A). After 10 rain washing of the column 
with Solvent A, the acetonitrile concentration in the elution solvent was 
raised over 35 min to 10.5% (v/v) then over 30 rain to 17.5% (total time: 
65 min) using linear gradients. Absorbance was read at 214 nm; 2-ml 
fractions were collected. Bioactive factions, which eluted between 39-44 
min (Fig. 1A), from five successive runs were pooled, evaporated to 
dryness, re-dissolved in 500/11 0.1% TFA and concentrated by RP 
HPLC on an analytical Vydac C18 column (250 x 4.6 mm, 300 A pore, 
5/~m bead), using 0.1% TFA (Solvent A) and 0.08% TFA in acetonitrile 
(Solvent B). 50-/11 aliquots were loaded onto the column equilibrated 
with Solvent A and the peptides eluted using the same gradient as above 
at a flow rate of 0.6 m/min. 
The peak, which eluted at 42.5~,3.5 rain, was collected manually 
(Peak 2, Fig. 1B) and further purified to apparent homogeneity by 
additional runs on the same column. The acetonitrile concentration was 
raised to 15% through a flatter linear gradient. Samples of approxi- 
mately 250400 pmol peptide (purified Peak 2) were then subjected to 
sequencing and mass analysis. 
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2.2. Characterization 
2.2.1. Peptide sequencing. Automated Edman degradation was car- 
ried out on an Applied Biosystem (Foster City, CA, USA) 470 A 
protein sequencer. Phenylthiohydantoin (PTH) derivatives were identi- 
fied by HPLC after automatic njection into an Applied Biosystem 120 
A analyser coupled to the sequencer. The methods used have been 
described elsewhere [16]. 
2,2.2. Analytical capillary electrophoresis ( CE ). The CE apparatus 
consisted of a Beckman (Palo Alto, CA, USA) Model P/ACE 2100 
automated system with autosampler and a Beckman Gold data collec- 
tion system. UV detection was at 200 nm and the data collection rate, 
5 Hz. A 50-/~m-i.d. eactivated silica capillary (Beckman) with a sepa- 
ration distance of 70 cm (total ength 77 cm) was maintained at 25°C. 
Experimental conditions are described in the legend to Fig. 4. 
2.2.3. Electrospray mass spectrometry (ESI-MS). A lyophilized 
sample of purified Peak 2 (Fig. 1B) was made up to 30#1 in an aqueous 
methanol solution (50:50 v/v) containing 1% acetic acid. ESI-MS anal- 
ysis was carried out by injecting the sample at a flow rate of 2/tl/min 
into an HP 5989 mass spectrometer (Hewlett Packard, San Fernando, 
CA, USA) equipped with an electrospray ion source (Analytica of 
Brandford type) and scanning over a mass range of 200 1100. The 
sum of several scans was used to obtain the final ESI-MS spectrum. 
For mass scale calibration, the multiply-charged molecular ions ob- 
tained from a separately introduced sample of heart myoglobin (aver- 
age molecular mass: 16,951.5 kDa) were employed. 
2.3. Synthetic peptide assembly 
Solid phase synthesis of the WGHE tetrapeptide was performed 
manually using chloromethylated resin containing 0.7 mmol/g Glu 
(OcHx). Boc-Trp, Boc-Gly and Boc-His (Dnp) were incorporated using 
BOP, as described elsewhere [19]. The peptide-resin compound was 
treated with thiophenol (50% in DMF) for 30 min to remove the Dnp 
group prior to final HF cleavage (1 h at 0°C in the presence of anisol). 
After trituration in ether, the crude compound was recovered in a 
water/acetic acid mixture (10:90) and lyophilized. 
Purification of the synthetic peptide was achieved by HPLC: the 
crude product was injected onto a semi-preparative column (Merck 
Hibar, 25 × 250 mm, 10/lm bead) and eluted through a gradient using 
an acetonitrile/water mixture containing 0.1% TFA. Fractions of 
> 95% purity as monitored by analytical HPLC were lyophilized as the 
purified compound. 
2.4. Bioassay 
All purification steps were monitored by measuring the ability of 
samples to promote IGF-I-induced [35S]sulphate incorporation into 
glycosaminoglycans (GAGs) in chick embryo leaflets, as described in 
Hetail elsewhere [14,20,21]. 
Recombinant human (rh) IGF-I was tested, either alone at 20 ng/ml, 
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or combined with either a reference human serum ultrafiltrate (1000-Da 
cut-off) or eluted fractions at appropriate dilutions. 
One arbitrary unit is defined as the amount of peptide with the same 
ability as 10% (v/v) serum ultrafiltrate to stimulate GAG synthesis in 
the presence of 20 ng/ml rhlGF-I over a 20-h incubation period. 
2.5. Statistical analysis 
Bioassays were repeated 3-5 times. Results are expressed as 
means + S.E.M. Differences between means were assessed by variance 
analysis (ANOVA and Bonferroni t-test) using SIGMASTAT software 
(Jansen Scientific Software, Erkrath, Germany). 
3. Results 
3.1. Purification of the LMW-GF tetrapeptide with growth 
promoting activity 
Pure IGFs are known to be weak sulfation factors in chick 
embryo cartilage when added alone to synthetic medium [6]. 
We previously showed that normal human serum contains at 
least one LMW-GF that potentiates IGF- I 's  stimulation of 
GAG biosynthesis in this tissue. Partial purification from 
human plasma was attempted at the time, using ultrafiltration 
and chromatography on molecular sieving gels [17]. 
In this study, semi-preparative RP HPLC was used to purify 
the single major peak with bioactivity recovered from Biogel P2 
gel permeation chromatography [20] (Fig. I A). Growth pro- 
moting activity (represented by the bar graph) emerged in two 
peaks between 11.6% and 13.5% acetonitrile. 
Analytical HPLC of the fractions with the highest activities 
revealed LMW-GF in two well-defined peaks (Peak 1 and Peak 
2, indicated by the arrows in Fig. 1B). Successive runs of Peak 
2, eluted at 43.0 rain (12.4% acetonitrile), led to purification to 
apparent homogeneity of LMW-GF peptide (not shown) which 
was then used for further characterization. 
3.2. Peptide characterization 
3.2.1. Sequence analysis. The primary structure of the 
human LMW-GF isolated was established as: Trp (242) Gly 
(163) His (105) - Glu (estimated at 47), or WGHE (interna- 
tional one-letter amino acid abbreviations). The values in 
brackets are the yields of the PTH-derivatives in pmol. The 
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Fig. 1. (A) Semi-preparative RP HPLC purification of LMW-GF. Bioactive Biogel P2 fractions were pooled and concentrated, then chromatographed 
on semi-preparative Vydac C18 columns using linear gradients of acetonitrile in 0.1% TFA. Fractions collected between 39 and 44 min, indicated 
by the horizontal line above the peak, were then purified further. (B) Analytical RP HPLC purification. The fractions from (A) were applied to 
analytical Vydac Ct8 columns and eluted using a flatter acetonitrile gradient. The arrows show where manual collection began and ended. Purified 
Peak 2 was used for sequencing, CE and ESI-MS analysis. The dotted lines indicate acetonitrile concentrations in the elution solvents. The inset bar 
graphs represent [35S]sulfate incorporation (arbitrary units per fraction). 
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! ig. 2. (A) Electrospray mass spectrometry (ESI-MS) analysis of purified Peak 2 (Fig. 1B) (capillary exit voltage: 220 V). (B) ESI-MS analysis of 
leak 3 in Fig. IB (capillary exit voltage: 190 V). Inset shows the same ESI-MS analysis with capillary exit voltage, 240 V. 
.,trong absorbance of the purified peptide at 280 nm confirmed 
U ae presence of a tryptophan residue (spectrophotometric 
measurement not shown). 
A minor sequence was also found, which proved to be a 
ontaminant from Peak 1 (Fig. 1B). Its sequence was: His (28) 
X (?) - Glu (estimated at 51) - Ser (12). It was suspected that 
X may be a tryptophan residue. It may equally have reflected 
!mild-up of the lag of PTH-Trp, the first residue of the major 
, omponent, but it was confirmed as a tryptophan by sequence 
, lata and mass spectrometry analysis of Peak 1 (Fig. 1 B) (man- 
tscript in preparation). 
Precise quantification of PTH-Glu proved impossible, owing 
o the presence of the minor sequence. 
3.2.2. Mass spectrometry analysis. Purified Peak 2 was 
.ubjected to electrospray mass spectrometry. As shown in Fig. 
'.A, several peaks were obtained. The mass averages for the two 
najor peaks were 528,6 and 349.6, respectively. The value for 
he highest peak, 528.6 Da (M + H+), agreed with that predicted 
)n the basis of the amino acid sequence of the purified peptide 
accurate mass: 527.2 Da). 
The unidentified component with a mass average value of 
349.6 corresponded a contaminant from Peak 3 in Fig. 213 and 
was therefore probably not biologically active. Furthermore, 
the inset (Fig. 2B) shows that this component was absent with 
a capillary exit voltage of 240 V. 
The two other peaks of 558.6 and 716.6 were shown to be 
contaminants from Peak 1 (manuscript in preparation). 
3.3. Biological activity 
On the basis of these findings, we prepared a synthetic 
WGHE tetrapeptide and compared its biological activity with 
that of the native peptide, purified Peak 2, in the l l -day-old 
chick embryo pelvic cartilage bioassay. 
As shown in Fig. 3: 
(1) neither the WGHE tetrapeptide at 30 ng/ml, nor rhlGF-I 
at 20 ng/ml affected basal [35S]sulfate uptake (104% and 117%, 
respectively: not statistically significant); 
(2) a combination of 20 ng/ml rhIGF-I and WGHE at five 
different concentrations (20-50 ng/ml) synergistically increased 
incorporation of the tracer, indicating enhanced GAG synthe- 
sis (and corroborating the results obtained with native peptide); 
(3) stimulation was dose-dependent and statistically signifi- 
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Fig. 3. [35S]Sulfate incorporation into glycosaminoglycans i  chick embryo pelvic leaflets. (A) Cartilages were incubated with: control culture medium 
(Bars 1 and 4); or 20 ng/ml rhlGF-I (Bar 2); or 30 ng/ml pure synthetic WGHE peptide (Bar 5); or rh IGF-I plus 10% (v/v) reference human serum 
ultrafiltrate (Bar 3); or rh IGF-I plus WGHE (Bar 6). Results are expressed as means + S.E.M, for five separate incubations. (B) Cartilages were 
incubated with 20 ng/ml rhlGF-I alone or in combination with synthetic WGHE peptide (at five concentrations). Results are expressed as the 
means + S.E.M. for 8 cartilages. * = P < 0.05; ** = P < 0.01 compared with controls (ANOVA). 
210 
O02S 
000b 
0.000 
RETENTION TIME (rain) 
Fig. 4. Analytical capillary electrophoresis of purified Peak 2 (Fig. 1B) 
and of synthetic WGHE. Experimental conditions: buffer: 25 mM so- 
dium borate, pH 8.3; pressure injection: 15 s; voltage: 25 kV; running 
temperature: 25°C; UV detection: 200 nm, 0.025 AUFS. Solid line, 
Peak 2; dashed line, Synthetic WGHE. 
cant at WGHE concentrations between 10 -9 and 10 -7 M. The 
effect was biphasic, with maximal stimulation (186%) at 
6.6 x 10 -8 M. Stimulation varied from one batch of cartilages 
to another, ranging from 165% to 205% above the (control) 
effect of rhlGF-I  alone. 
4. Discussion 
This is the first report of isolation from human plasma and 
structural characterization f the tetrapeptide, WGHE, which 
modulates the effects of IGF-I  on proteoglycan synthesis in 
chick embryo cartilage in culture. 
Mass spectrometry analysis yielded a molecular mass which 
agreed with that deduced from the primary sequence. 
Peptides from Peak 1 (Fig. 1 B) were recovered in Peak 2 (Fig. 
1B), but contamination was less than 15% on the basis of the 
area under the peak in analytical capillary electrophoresis 
(Fig. 4). 
Confirmation of the nature and activity of the tetrapeptide 
was obtained using a synthetic WGHE peptide which had the 
identical migration time in borate buffer capillary electrophore- 
sis and, in combination with rhlGF-I,  exhibited the same 
biphasic, dose-dependent stimulation of [35S]sulfate uptake in 
pelvic cartilage xplants. This classical biphasic biological effect 
is also observed in GAG synthesis timulated by vitamin D3 
[22] or the tripeptide, GHK [23]. 
It remains to be determined whether or not the effects of the 
WGHE tetrapeptide are species-specific, or peculiar to a partic- 
ular stage of development, or limited to a single biological 
activity, such as GAG sulfation. Its presence in normal human 
plasma indicates that it may play a role in the regulation of 
growth and differentiation or it may likewise be involved in 
cartilage growth disorders. Jacob et al. [24] recently demon- 
strated that LMW-GF bioactivity ([35S]sulfate incorporation) 
was drastically reduced in patients with chronic renal failure 
and was restored to normal evels after successful kidney trans- 
plantation. This would suggest that the human kidney may be 
involved in LMW-GF biosynthesis and/or processing. The abil- 
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ity of IGF-I  to enhance matrix synthesis in normal cartilage is 
well established, both in vivo [25] and in vitro [26,27]. However, 
both IGFs are produced ubiquitously, together with specific, 
high-affinity binding proteins (IGFBPs), and their biological 
activities are mediated by the Type 1 IGF receptor [28,29]. In 
so complex a system, WGHE tetrapeptides would constitute an 
abundant source of bioactive probe in investigating structure/ 
function relationships in the IGF-I  signaling pathway. 
The WGHE motif is present in several human and mammal- 
ian cell proteins, like the carboxy-terminal domain of human 
actin-binding protein (ABP-280) at amino acid position, 2632- 
2635 [30], or the human high MW kininogen sequence, at posi- 
tion 431434 [31,32]. Kininogens are potent inhibitors of thiol- 
proteases and have been implicated in the pathogenesis of in- 
flammation. Recent findings uggest that the renal vasodilatory 
effect of IGF-I is mediated by kinins [33]. We suspect hat our 
WGHE tetrapeptide may be produced by a variety of cell types 
and/or be generated by proteolysis of these high MW proteins. 
The extracellular matrix (ECM) is an important template in 
the regulation of cell responses to growth factors [34-36], al- 
though the mechanisms involved remain to be elucidated. Sul- 
fated GAGs are major constituents of the ECM and, through 
enhanced synthesis, are predominant in the late post-inflamma- 
tory phase of wound repair [37]. Negative or positive regulation 
of matrix production would depend on the proportions of spe- 
cific proteases present during tissue regeneration. Here, the 
WGHE tetrapeptide may be a minimum sequence of an uniden- 
tified polypeptide involved in the maturation of the ECM, pos- 
sibly by inhibiting ECM degrading enzymes, and in promoting 
the completion of wound repair. 
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